Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shu-Chin Alicia Lai"'
Autor:
Christa I. DeVette, Harika Gundlapalli, Shu-Chin Alicia Lai, Curtis P. McMurtrey, Ashley R. Hoover, Hem R. Gurung, Wei R. Chen, Alana L. Welm, William H. Hildebrand
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Cancer immunotherapy continues to make headway as a treatment for advanced stage tumors, revealing an urgent need to understand the fundamentals of anti-tumor immune responses. Noteworthy is a scarcity of data pertaining to the breadth and specificit
Externí odkaz:
https://doaj.org/article/cbf817d65dfb42c7a8c3960ab9cab300
Autor:
Huseyin Atakan Ekiz, Shu-Chin Alicia Lai, Harika Gundlapalli, Fadi Haroun, Matthew A. Williams, Alana L. Welm
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small
Externí odkaz:
https://doaj.org/article/77d2d9b52fab421a9e678fdea8ee710c
Autor:
Alana L. Welm, Elvelyn Fernandez, Amanda Jiang, H. Atakan Ekiz, Harika Gundlapalli, Shu-Chin Alicia Lai
Table S2 - Genes in immune cell clusters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f542407d160b6c814c509b33f4445e
https://doi.org/10.1158/2159-8290.22540447.v1
https://doi.org/10.1158/2159-8290.22540447.v1
Autor:
Alana L. Welm, Elvelyn Fernandez, Amanda Jiang, H. Atakan Ekiz, Harika Gundlapalli, Shu-Chin Alicia Lai
Immunotherapy has potential to prevent and treat metastatic breast cancer, but strategies to enhance immune-mediated killing of metastatic tumors are urgently needed. We report that a ligand-independent isoform of Ron kinase (SF-Ron) is a key target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a48ca7c65f60fb1712380a4aa11ee3e
https://doi.org/10.1158/2159-8290.c.6549382.v1
https://doi.org/10.1158/2159-8290.c.6549382.v1
Publikováno v:
Cancer Research. 81:PS17-24
Metastatic breast cancer is the overwhelming cause of breast cancer mortality and is still incurable. The rapid development of immunotherapy is an exciting new area of research in metastatic breast cancer. However, the extreme immunosuppressive tumor
Autor:
H. Atakan Ekiz, Amanda Jiang, Alana L. Welm, Elvelyn Fernandez, Harika Gundlapalli, Shu-Chin Alicia Lai
Publikováno v:
Cancer Discov
Immunotherapy has potential to prevent and treat metastatic breast cancer, but strategies to enhance immune-mediated killing of metastatic tumors are urgently needed. We report that a ligand-independent isoform of Ron kinase (SF-Ron) is a key target
Autor:
William H. Hildebrand, Harika Gundlapalli, Wei R. Chen, Hem R. Gurung, Curtis McMurtrey, Alana L. Welm, Christa I. DeVette, Ashley R. Hoover, Shu-Chin Alicia Lai
Publikováno v:
Oncoimmunology
OncoImmunology, Vol 9, Iss 1 (2020)
OncoImmunology, Vol 9, Iss 1 (2020)
Cancer immunotherapy continues to make headway as a treatment for advanced stage tumors, revealing an urgent need to understand the fundamentals of anti-tumor immune responses. Noteworthy is a scarcity of data pertaining to the breadth and specificit
Autor:
Alana L. Welm, Matthew A. Williams, Fadi Haroun, Huseyin Atakan Ekiz, Harika Gundlapalli, Shu Chin Alicia Lai
Publikováno v:
OncoImmunology, Vol 7, Iss 9 (2018)
The advent of immune checkpoint blockade as a new strategy for immunotherapy has changed the outlook for many aggressive cancers. Although complete tumor eradication is attainable in some cases, durable clinical responses are observed only in a small
Publikováno v:
Cancer Immunology Research. 6:A30-A30
Metastasis is the cause of death for nearly all types of cancer, including breast cancer. An exciting new area of research in metastatic breast cancer centers on immune therapy. Although new immune checkpoint blockade therapies have provided benefit